ABBV vs. HOLX: A Head-to-Head Stock Comparison

Updated on October 8, 2025

Here’s a clear look at ABBV and HOLX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	ABBV	HOLX
Company Name	AbbVie Inc.	Hologic, Inc.
Country	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Health Care Equipment & Supplies
Market Capitalization	413.22 billion USD	14.98 billion USD
Exchange	NYSE	NasdaqGS
Listing Date	January 2, 2013	March 1, 1990
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of ABBV and HOLX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ABBV vs. HOLX: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	ABBV	HOLX
5-Day Price Return	4.82%	-0.22%
13-Week Price Return	23.58%	4.61%
26-Week Price Return	11.64%	9.71%
52-Week Price Return	18.84%	-15.00%
Month-to-Date Return	1.02%	-0.22%
Year-to-Date Return	31.63%	-6.59%
10-Day Avg. Volume	6.76M	1.56M
3-Month Avg. Volume	5.66M	2.13M
3-Month Volatility	23.82%	25.21%
Beta	0.36	0.70

Profitability

Return on Equity (TTM)

ABBV

95.59%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

In the upper quartile for the Biotechnology industry, ABBV’s Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

HOLX

11.51%

Health Care Equipment & Supplies Industry

Max: 29.93%
Q3: 16.99%
Median: 9.28%
Q1: 5.10%
Min: -12.52%

HOLX’s Return on Equity of 11.51% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.

ABBV vs. HOLX: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Net Profit Margin (TTM)

ABBV

6.45%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

HOLX

13.79%

Health Care Equipment & Supplies Industry

Max: 24.41%
Q3: 13.71%
Median: 10.08%
Q1: 5.96%
Min: -5.58%

A Net Profit Margin of 13.79% places HOLX in the upper quartile for the Health Care Equipment & Supplies industry, signifying strong profitability and more effective cost management than most of its peers.

ABBV vs. HOLX: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Operating Profit Margin (TTM)

ABBV

18.80%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

HOLX

17.52%

Health Care Equipment & Supplies Industry

Max: 31.09%
Q3: 18.11%
Median: 15.07%
Q1: 8.48%
Min: -0.28%

HOLX’s Operating Profit Margin of 17.52% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.

ABBV vs. HOLX: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Profitability at a Glance

Symbol	ABBV	HOLX
Return on Equity (TTM)	95.59%	11.51%
Return on Assets (TTM)	2.73%	6.32%
Net Profit Margin (TTM)	6.45%	13.79%
Operating Profit Margin (TTM)	18.80%	17.52%
Gross Profit Margin (TTM)	70.93%	56.34%

Financial Strength

Current Ratio (MRQ)

ABBV

0.74

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

ABBV’s Current Ratio of 0.74 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

HOLX

3.55

Health Care Equipment & Supplies Industry

Max: 5.19
Q3: 3.00
Median: 2.13
Q1: 1.44
Min: 0.86

HOLX’s Current Ratio of 3.55 is in the upper quartile for the Health Care Equipment & Supplies industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.

ABBV vs. HOLX: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ABBV

49.22

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

HOLX

0.52

Health Care Equipment & Supplies Industry

Max: 1.61
Q3: 0.76
Median: 0.45
Q1: 0.14
Min: 0.00

HOLX’s Debt-to-Equity Ratio of 0.52 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ABBV vs. HOLX: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Interest Coverage Ratio (TTM)

ABBV

2.70

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

HOLX

58.29

Health Care Equipment & Supplies Industry

Max: 56.35
Q3: 25.56
Median: 9.60
Q1: 3.78
Min: -26.49

With an Interest Coverage Ratio of 58.29, HOLX demonstrates a superior capacity to service its debt, placing it well above the typical range for the Health Care Equipment & Supplies industry. This stems from either robust earnings or a conservative debt load.

ABBV vs. HOLX: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Financial Strength at a Glance

Symbol	ABBV	HOLX
Current Ratio (MRQ)	0.74	3.55
Quick Ratio (MRQ)	0.48	2.59
Debt-to-Equity Ratio (MRQ)	49.22	0.52
Interest Coverage Ratio (TTM)	2.70	58.29

Growth

Revenue Growth

ABBV vs. HOLX: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ABBV vs. HOLX: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ABBV

2.71%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ABBV’s Dividend Yield of 2.71% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

HOLX

0.00%

Health Care Equipment & Supplies Industry

Max: 4.15%
Q3: 1.76%
Median: 0.79%
Q1: 0.00%
Min: 0.00%

HOLX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ABBV vs. HOLX: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Dividend Payout Ratio (TTM)

ABBV

226.84%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

HOLX

0.00%

Health Care Equipment & Supplies Industry

Max: 160.00%
Q3: 66.60%
Median: 27.49%
Q1: 0.00%
Min: 0.00%

HOLX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ABBV vs. HOLX: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Dividend at a Glance

Symbol	ABBV	HOLX
Dividend Yield (TTM)	2.71%	0.00%
Dividend Payout Ratio (TTM)	226.84%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

ABBV

111.05

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

At 111.05, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

HOLX

27.04

Health Care Equipment & Supplies Industry

Max: 67.29
Q3: 47.01
Median: 30.94
Q1: 23.91
Min: 10.79

HOLX’s P/E Ratio of 27.04 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

ABBV vs. HOLX: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Price-to-Sales Ratio (TTM)

ABBV

7.16

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

ABBV’s P/S Ratio of 7.16 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

HOLX

3.73

Health Care Equipment & Supplies Industry

Max: 9.49
Q3: 5.41
Median: 2.86
Q1: 2.07
Min: 0.74

HOLX’s P/S Ratio of 3.73 aligns with the market consensus for the Health Care Equipment & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ABBV vs. HOLX: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Price-to-Book Ratio (MRQ)

ABBV

261.01

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

HOLX

3.00

Health Care Equipment & Supplies Industry

Max: 10.85
Q3: 6.56
Median: 3.53
Q1: 2.36
Min: 0.71

HOLX’s P/B Ratio of 3.00 is within the conventional range for the Health Care Equipment & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

ABBV vs. HOLX: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Valuation at a Glance

Symbol	ABBV	HOLX
Price-to-Earnings Ratio (TTM)	111.05	27.04
Price-to-Sales Ratio (TTM)	7.16	3.73
Price-to-Book Ratio (MRQ)	261.01	3.00
Price-to-Free Cash Flow Ratio (TTM)	22.91	16.43